COVID-19, bLOod Coagulation and Thrombosis

Coronavirus 2 (SARS-CoV2) has been identified as the pathogen responsible for severe acute
respiratory syndrome associated with severe inflammatory syndrome and pneumonia (COVID-19).

Described at the end of 2019 in China, the pandemic sees the number of patients increasing
worldwide, Europe being still in the ascending phase of the epidemic and the American
continent at the very beginning of it.

Haemostasis abnormalities have been shown to be associated with a poor prognosis in these
patients with this pneumonia. In a Chinese series of 183 patients, the hemostasis balance
including thrombin time, fibrinogenemia, fibrin degradation products and antithrombin III
were within normal limits. Only the D-Dimer assay was positive in the whole cohort with an
average rate of 0.66 µg / mL (normal <50 µg / mL). These hemostasis parameters were abnormal
mainly in patients who died during their management; the levels of D-dimers and fibrin
degradation products were significantly higher while the antithrombin III was reduced. The
findings on the particular elevation of D-dimers in deceased patients as well as the
significant increase in thrombin time were also reported in another series. Higher numbers of
pulmonary embolisms have been reported in patients with severe form of SARS-COV2 (data in
press).

This research is based on the hypothesis that the existence of deep vein thrombosis (DVT)
could make it possible to screen patients at risk of pulmonary embolism and to set up a
curative anticoagulation. This is all the more important since the occurrence of a pulmonary
embolism can clearly worsen the right ventricular failure possibly observed during mechanical
ventilation in these patients.

Cohort study, non-interventional, multicentric, prospective, non-comparative, longitudinal.

The main objective of the research is to describe the prevalence of deep vein thrombosis in
patients hospitalized in intensive care for acute respiratory failure linked to documented
SARS-COV2 pneumonia, within 24 hours of their admission.

The secondary objectives of the research are:

- Identify the factors associated with the existence of deep vein thrombosis

- Describe the relationship between the inflammatory status of patients on admission and
the existence of DVT during follow-up.

- Describe the relationship between the results of the hemostasis assessment and the
existence of deep vein thrombosis during follow-up.

- Describe the relationship between a right ventricular failure or dysfunction during
follow-up and the existence of DVT.

- Describe the relationship between mortality and the existence of DVT, within 28 days of
the patient's admission to intensive care or intensive care. Describe the lung
parenchyma if a CT scan is performed